UCB pays up to $1.1B for Antengene TCE — Belgian drugmaker enters bispecific arena

UCB licensed ATG‑201, Antengene’s preclinical CD19/CD3 bispecific T‑cell engager (TCE), in a deal worth up to $1.1 billion to expand into novel T‑cell engager modalities for immune disorders. The agreement gives UCB exclusive global rights to develop, manufacture and commercialize ATG‑201 and includes upfront and near‑term milestones plus additional development and commercial payments tied to progress. The move marks UCB’s first major step into TCEs and signals broader pharma interest in adapting T‑cell engager platforms for autoimmune and inflammatory indications beyond oncology.